Ultomiris for Paroxysmal Nocturnal Hemoglobinuria

News
Article

Ultomiris

ULTOMIRIS (ravulizumab-cwvz , Alexion Pharmaceuticals, Inc.)

Indications: treatment of adult patients with paroxysmal nocturnal hemoglobinuria

Dosage: intravenous infusion only

  • 40 kg ≤ X< 60 kg – 2,400mg leading, 3,000 mg maintenance

  • 60kg ≤ X < 100kg – 2,700mg leading, 3,300mg maintenance

  • 100kg ≤  X – 3,000mg leading, 3,600 maintenance

Contraindications: patients with unresolved Neisseria Meningitidis infection.

 

​Click here for more prescribing information

Related Content
FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma

FDA Grants Tovorafenib Approval to Treat Relapsed or Refractory Pediatric Low-Grade Glioma

April 23rd 2024
Article

The approval for tovorafenib (Ojemda) was based on data from the phase 2 FIREFLY-1 trial, in which the therapy demonstrated an overall repose rate of 67%.

Over the Counter podcast

Episode 8: Stay in Sync with Innovations in Medication Decision Support

August 6th 2020
Podcast

Episode 8 of Over the Counter discusses the new and exciting modernizations in the medication decision support space.

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

FDA Roundup: Biosimilars, Boxed Warning Added for CAR T-Cell Therapies

April 19th 2024
Article

Check out important updates from the FDA for the week of April 15.

Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval

Stelara Biosimilar Ustekinumab-aekn Recieves FDA Approval

April 19th 2024
Article

This approval is the second biosimilar approval for manufacturer Alvotech.

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

FDA Accepts GSK's BLA for 5-in-1 Meningococcal Vaccine

April 16th 2024
Article

The company’s investigational ABCWY vaccine candidate will be reviewed by the FDA by February 14, 2025.

Rx Roundup: Quiz of the Week — April 12, 2024

Rx Roundup: Quiz of the Week — April 12, 2024

April 12th 2024
Article

Test your pharmacy news knowledge with our weekly quiz.

© 2024 MJH Life Sciences

All rights reserved.